CCC
AZN icon

Crescent Capital Consulting’s AstraZeneca AZN Stock Holding History

Crescent Capital Consulting’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$221K Hold
1,901
– – 0.04% 167
2021
Q3 		$228K Hold
1,901
– – 0.04% 168
2021
Q2 		$228K Hold
1,901
– – 0.04% 163
2021
Q1 		$190K Hold
1,901
– – 0.04% 183
2020
Q4 		$190K Buy
+1,901
New +$201K 0.05% 157

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Crescent Capital Consulting's AZN Position: Q4 2021 in Review

Crescent Capital Consulting held its AstraZeneca (AZN) position steady in Q4 2021 at 1,901 shares worth $221K. The position accounts for 0.04% of the portfolio, ranked #167.

Crescent Capital Consulting first reported a position in AZN in Q4 2020 and has held it in 5 quarters since. The position peaked at $228K in Q3 2021. 949 funds tracked by Wall St. Rank hold AZN as of Q4 2021.

  • Crescent Capital Consulting held 1,901 shares of AstraZeneca worth $221K as of Q4 2021.
  • Crescent Capital Consulting left its AstraZeneca share count unchanged in Q4 2021.
  • AstraZeneca made up 0.04% of Crescent Capital Consulting's portfolio in Q4 2021, its #167 holding.
  • Crescent Capital Consulting first reported a position in AstraZeneca in Q4 2020 and has held it in 5 quarters since.
  • Crescent Capital Consulting's AstraZeneca position peaked at $228K in Q3 2021.
  • 949 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.